"SPPI has been the topic of several analyst reports. RBC Capital raised their price target on Spectrum Pharmaceuticals from $12 to $13 and gave the stock an “outperform” rating in a research report"
Source: Spectrum Pharmaceuticals Receives Average Rating of “Buy” from Analysts
Dakota Financial News
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference. The live presentation will occur at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) on Wednesday, September 16, 2015.
"The mean short term price target for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has been established at $8 per share. The higher price target estimate is at $10"
Source: Zacks Rating on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
American Trade Journal
I thin BDSI will receive excellent approval in October. Price target is $14 to $21.